Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies
Cell & Gene Therapy Insights 2021; 7(8), 1159
Published: 4 October 2021
Watch the video or read the poster to learn about:
- Optimizing plasmid transfection-based production of AAV in suspension culture using single-use bioreactors
- Implementing scalable and robust technologies for efficient purification of biologically active AAV.
- Scalable technologies and Enterprise solutions for advancing viral vector manufacturing